Short answer
Fulgent Genetics, Inc. (FLGT) filed an 8-K current report with the SEC on July 30, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Q2 fiscal 2026 results for quarter ended June 30, 2026.
Fulgent Genetics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 fiscal 2026 results for quarter ended June 30, 2026
- Press release issued July 30, 2026
- Detailed financial results furnished as Exhibit 99.1 for investor review
Item 7.01 · Regulation FD Disclosure
- Updated investor presentation released July 30, 2026, providing refreshed business information for the investment community
- Presentation available through Fulgent Genetics’ investor-relations website and furnished as Exhibit 99.2
- Reg FD materials furnished, not filed, limiting Section 18 liability and automatic incorporation into registration statements
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $85.4M, up 20.1% sequentially, but GAAP gross margin fell to 30.1% from 42.1% year over year
- GAAP loss widened to $29.5M, or $1.05 per share, versus $19.0M, or $0.62, in Q2 2025
- Billing-system transition delays are reducing collections and prompted lower 2026 revenue guidance of $330.0M-$340.0M
- Stock repurchases totaled $23.8M for approximately 1.5M shares in Q2, supporting per-share metrics but reducing liquidity
- Cash and investments totaled $551.5M, excluding an anticipated $106.1M tax refund, providing substantial funding for losses and therapeutics development
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Fulgent Genetics, Inc. 8-K filings
Get the next FLGT 8-K as it lands
Follow FLGT for push alerts, or ask the research agent what this filing means.